- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00147121
Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)
September 20, 2016 updated by: Haruhiko Fukuda
Rituximab + Standard CHOP (R・S-CHOP) vs Rituximab+ Bi-weekly CHOP (R・Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-grade B-cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203)
To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Since currently there is no standard therapy for untreated advanced-stage low-grade B-cell lymphoma, Phase 2/3 study was planned.
Comparison(s): An intensified bi-weekly version by shortening the intervals of both rituximab and CHOP therapies using G-CSF, compared to the tri-weekly R-CHOP regimen.
Study Type
Interventional
Enrollment (Actual)
300
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Aich
-
Nagoya,Naka-ku,Sannomaru,4-1-1, Aich, Japan, 460-0001
- Nagoya Medical Center
-
-
Aichi
-
Aichi-gun,Nagakute,Yazako,Karimata,21, Aichi, Japan, 480-1195
- Aichi Medical University
-
Nagoya,Chikusa-ku,Kanokoden,1-1, Aichi, Japan, 464-8681
- Aichi Cancer Center Hospital
-
Nagoya,Mizuho-ku,Mizuho-cho,Kawasumi,1, Aichi, Japan, 467-8601
- Nagoya City University Hospital
-
Nagoya,Showa-ku, Tsurumai-cho,65, Aichi, Japan, 466-8550
- Nagoya University School of Medicine
-
Nagoya,Showa-ku,Myoken-cho,2-9, Aichi, Japan, 466-8650
- Nagoya Daini Red Cross Hospital
-
-
Akita
-
Akita,Hondo,1-1-1, Akita, Japan, 010-8543
- Akita University School of Medicine
-
-
Chiba
-
Chiba,Chuo-ku,Nitona-cho,666-2, Chiba, Japan, 260-8717
- Chiba Cancer Center Hospital
-
Kashiwa,Kashiwanoha,6-5-1, Chiba, Japan, 277-8577
- National Cancer Center Hospital East
-
-
Ehime
-
Shitsukawa,Toon, Ehime, Japan, 791-0295
- Ehime University Hospital
-
-
Fukui
-
Yoshida-gun,Matsuoka,Shimoaizuki,23-3, Fukui, Japan, 910-1193
- University of Fukui Hospital
-
-
Fukuoka
-
Fukuoka,Jonan-ku,Nanakuma,7-45-1, Fukuoka, Japan, 814-0180
- School of Medicine,Fukuoka University
-
Fukuoka,Minami-ku,Notame,3-1-1, Fukuoka, Japan, 811-1395
- National Kyushu Cancer Center
-
FukuokaChuo-ku,Jigyohama,1-8-1, Fukuoka, Japan, 810-0065
- National Hospital Organization Kyusyu Medical Center
-
Kitakyushu,Yahatanishi-ku,Iseigaoka,1-1, Fukuoka, Japan, 807-0804
- University of Occupational and Environmental Health
-
-
Fukushima
-
Kohriyama,Nishinouchi,2-5-20, Fukushima, Japan, 963-8022
- Ohta Nishinouchi Hospital
-
-
Gunma
-
Maebashi,Showa,3-39-15, Gunma, Japan, 371-8511
- Gunma University
-
-
Hokkaido
-
Sapporo,Shiroishi-ku,Higashi-sapporo,6-5-1, Hokkaido, Japan, 003-0006
- Sapporo Hokuyu Hospital
-
Sapporo,Shiroishi-ku,Kikusui,4-2-3-54, Hokkaido, Japan, 003-0804
- National Hospital Organization Hokkaido Cancer Center
-
-
Ishikawa
-
Kahoku-gun,Uchinada-machi,Daigaku,1-1, Ishikawa, Japan, 920-0265
- Kanazawa Medical University
-
-
Kagoshima
-
Kagoshima,Kamoikeshinmachi,11-23, Kagoshima, Japan, 890-0064
- Imamura Bun-in Hospital
-
Kagoshima,Sakuragaoka,8-35-1, Kagoshima, Japan, 890-8520
- Kagoshima University,Faculty of Medicine
-
-
Kanagawa
-
Isehara,Shimokasuya,143, Kanagawa, Japan, 259-1193
- Tokai University School of Medicine
-
Yokohama,Asahi-ku,Yasashi-cho,1197-1, Kanagawa, Japan, 241-0811
- St.Marianna University School of Medicine,Yokohama City Seibu Hospital
-
-
Kumamoto
-
Kumamoto,Honjo,1-1-1, Kumamoto, Japan, 860-8556
- Kumamoto University Medical School
-
Kumamoto,Ninomaru,1-5, Kumamoto, Japan, 860-0008
- Nho Kumamoto Medical Center
-
-
Kyoto
-
Kyoto,Kamigyo-ku,Kawaramachi-Hirokoji,465, Kyoto, Japan, 602-0841
- Kyoto Prefectural University of Medicine
-
-
Mie
-
Tsu,Edobashi,2-174, Mie, Japan, 514-8507
- Mie University School of Medicine
-
-
Miyagi
-
Sendai,Aoba-ku,Seiryo-machi,1-1, Miyagi, Japan, 980-8574
- Tohoku University Hospital
-
-
Nagasaki
-
Nagasaki,Sakamoto,1-7-1, Nagasaki, Japan, 852-8501
- Nagasaki University Hospital
-
Oomura,Kubara,2-1001-1, Nagasaki, Japan, 856-8562
- Nagasaki Medical Center
-
Sasebo,Hirasemachi,9-3, Nagasaki, Japan, 857-8511
- Sasebo City General Hospital
-
-
Niigata
-
Niigata,Kawagishi-cho,2-15-3, Niigata, Japan, 951-8566
- Niigata Cancer Center Hospital
-
-
Oita
-
Oita,Bunyo,476, Oita, Japan, 870-8511
- Oita Prefectural Hospital
-
-
Okinawa
-
Nakagami,Nishihara,Uehara,207, Okinawa, Japan, 903-0125
- Faculty of Medicine,University of Ryukyus
-
-
Saga
-
Saga,Nabeshima,5-1-1, Saga, Japan, 849-8501
- Faculty of Medicine, Saga University
-
-
Saitama
-
Kita-adachi,Ina,Komuro,818, Saitama, Japan, 362-0806
- Saitama Cancer Center
-
-
Shiga
-
Moriyama,Moriyama,5-4-30, Shiga, Japan, 524-8524
- Shiga Medical Center for Adults
-
-
Shizuoka
-
Hamamatsu,Handayama,1-20-1, Shizuoka, Japan, 431-3192
- Hamamatsu University School of Medicine
-
-
Tokyo
-
Bunkyo-ku,Honkomagome,3-18-22, Tokyo, Japan, 113-8677
- Tokyo Metropolitan Komagome Hospital
-
Chuo-kum,Tsukiji, 5-1-1, Tokyo, Japan, 104-0045
- National Cancer Center Hospital
-
Komae,Izumihoncho,4-11-1, Tokyo, Japan, 201-8601
- Jikei University,Daisan Hospital
-
Minato-ku,Nishishinbashi,3-25-8, Tokyo, Japan, 105-8461
- Jikei University Hospital
-
Mitaka,Shinkawa,6-20-2, Tokyo, Japan, 181-8611
- Kyorin University School of Medicine
-
Shinjuku-ku,Nishi-shinjuku,6-7-1, Tokyo, Japan, 160-0023
- Tokyo Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 69 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histological confirmed, low-grade B-cell lymphoma except mantle cell lymphoma and histologic transformation to DLBCL
- CD20-positive
- Ann Arbor CS III or IV
- Lymphoma cell count in PB≦10,000/mm3
- 20<=age<=69
- ECOG PS 0-2
- Bidimensionally measurable disease >1.5cm in a single dimension by CT scans
- No prior chemotherapy, radiotherapy, interferon-alfa, or antibody therapy
- Normal BM, hepatic, renal, cardiac, and pulmonary function
- Written informed consent
Exclusion Criteria:
- CNS involvement
- Glaucoma
- DM treated by insulin
- Uncontrollable HT
- AP, AMI
- Positive HBs antigen
- seropositive to HCV
- seropositive to HIV
- Interstitial pneumonitis, pulmonary fibrosis, or emphysema
- Severe infection
- Liver cirrhosis
- Double cancer
- Pregnant or lactating
- Patients who desire auto PBST after CR
- Patients treated with major tranquilizer or antidepressant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 1
Rituximab+Standard CHOP
|
Rituximab + Standard CHOP
|
EXPERIMENTAL: 2
Rituximab+bi-Weekly CHOP
|
Rituximab + Bi-weekly CHOP
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CR rate (phase II)
Time Frame: during the study conduct
|
during the study conduct
|
PFS (phase III)
Time Frame: during the study conduct
|
during the study conduct
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ORR, PFS, OS, Safety (phase II)
Time Frame: during the study conduct
|
during the study conduct
|
OS, Safety (phase III)
Time Frame: during the study conduct
|
during the study conduct
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Kensei Tobinai, M.D.,Ph.D., National Cancer Center Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K; JCOG0203 Collaborators. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematol. 2018 Nov;5(11):e520-e531. doi: 10.1016/S2352-3026(18)30155-8.
- Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Takeuchi K, Nawano S, Terauchi T, Hotta T. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol. 2011 Oct 20;29(30):3990-8. doi: 10.1200/JCO.2011.34.8508. Epub 2011 Sep 19.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2002
Primary Completion (ACTUAL)
February 1, 2010
Study Completion (ACTUAL)
February 1, 2010
Study Registration Dates
First Submitted
September 5, 2005
First Submitted That Met QC Criteria
September 5, 2005
First Posted (ESTIMATE)
September 7, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
September 22, 2016
Last Update Submitted That Met QC Criteria
September 20, 2016
Last Verified
September 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- JCOG0203
- C000000033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, B-Cell
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
Nathan DenlingerBristol-Myers SquibbRecruitingB-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditionsUnited States
-
AstraZenecaRecruitingFollicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin LymphomaKorea, Republic of, United States, Japan, Australia, Taiwan
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Massachusetts General HospitalVarian Medical SystemsRecruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University of ChicagoMerck Sharp & Dohme LLCRecruitingLymphoma | Lymphoma, B-Cell | B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell LymphomaUnited States
-
University of NebraskaBristol-Myers SquibbRecruitingFollicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Active, not recruitingDiffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma... and other conditionsUnited States
-
Curocell Inc.RecruitingHigh-grade B-cell Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Transformed Follicular Lymphoma (TFL) | Refractory Large B-cell Lymphoma | Relapsed Large B-cell LymphomaKorea, Republic of
Clinical Trials on Rituximab + Standard CHOP
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanTerminatedNon-Hodgkin's LymphomaJapan
-
Sinocelltech Ltd.Unknown
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedDiffuse, Large B-Cell, LymphomaChina
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Completed
-
Nantes University HospitalCompletedLymphoma, Large-Cell, DiffuseFrance
-
French National Agency for Research on AIDS and...Hoffmann-La RocheTerminated
-
Lymphoma Study AssociationAssociation pour le Développement de la Recherche Clinique et Informatique...Completed
-
Weill Medical College of Cornell UniversityMillennium Pharmaceuticals, Inc.CompletedNon-Hodgkin's LymphomaUnited States
-
NCIC Clinical Trials GroupCompleted
-
University Hospital TuebingenHoffmann-La RocheCompletedPrimary Gastric Diffuse-Large B-Cell LymphomaGermany